Nimotuzumab is not an Erbitux-like drug,…but an EGFR MAb with very different binding properties…
I think government and third-party payers are apt to view these drugs as fungible in much the same way they do for, say, statins. When Zocor went off-patent in 2006, it adversely affected the sales of Lipitor as payers pushed for (and got) a high degree of “therapeutic substitution” with generic Zocor.
The situation with the EGFr class is not directly analogous, but I think it’s naïve to assume that Erbitux biosimilars won’t have an adverse effect on the business proposition for Nimo.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.